Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Therion Biologics Corp.

Latest From Therion Biologics Corp.

Appointments: IRX Therapeutics, Therachon, Mission Therapeutics and bluebird bio

This week’s roundup includes CEO appointments by Smart Matrix and IRX Therapeutics, with various senior level appointments by companies including Therachon, Mission Therapeutics and bluebird bio.

Appointments BioPharmaceutical

Chiasma names new CEO

Chiasma, a US privately held biopharma company developing octreotide capsules for the orphan condition acromegaly, has appointed Mark Leuchtenberger president and CEO. Mr Leuchtenberger brings 25 years of industry experience to Chiasma, including CEO positions with Acusphere, Rib-X Pharmaceuticals, Targanta Therapeutics and Therion Biologics. From 1996 to 2002, he held multiple senior positions with Biogen, where he managed North American and international commercial operations. He currently serves as advisory board chair of the Massachusetts Emerging Technology Fund, MassDevelopment, and as a trustee and member of the Medical Education Committee, Beth Israel Deaconess Medical Center. And is also a board member of the Massachusetts Biotechnology Council.

Metabolic Disorders Israel

BMS explores OS potential of prostate cancer vaccine with $975m deal

Bristol-Myers Squibb is paying $60m upfront for an exclusive option to Prostvac, Bavarian Nordic's Phase III-stage prostate-specific antigen (PSA)-targeting cancer immunotherapy in development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).


Gardasil Pushes Vaccine Prices--and Markets--to New Heights

The Gardasil launch is arguably the event with the greatest impact on the public perception of the new opportunities in vaccines, since it offers the promise of preventing future cervical cancers by vaccinating young adolescent girls. The commercialization of Gardasil has been front page news throughout the summer.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Therion Biologics Corp.
  • Senior Management
  • Richard Woodrich, SVP, Bus Dev.
    Michael Wyand, PhD, SVP, R&D
  • Contact Info
  • Therion Biologics Corp.
    Phone: (617) 876-7779
    76 Rogers St.
    Cambridge, MA 02142